Oric Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 24, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2020-04-23

Reporting Person: Svennilson Peter (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	75000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (3500000)		Indirect
Series B Preferred Stock	$		Common Stock (625000)		Indirect
Series C Preferred Stock	$		Common Stock (416666)		Indirect
Series D Preferred Stock	$		Common Stock (151515)		Indirect

Footnotes

F1: The shares are held of record by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP. The Reporting Person is a Managing Partner of TCG II GP and may be deemed to share voting and investment power with respect to the shares reported herein. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any.

F2: The number of shares of Common Stock reflects a one-for-four reverse stock split of the Issuer's Common Stock and Preferred Stock which became effective April 21, 2020. Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.